18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.

[1]  P. Lambin,et al.  Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. , 2009, European journal of cancer.

[2]  M. Halpern,et al.  Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? , 2008, CA: a cancer journal for clinicians.

[3]  G. Bepler,et al.  Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Joore,et al.  Decision-analytic modeling to assist decision making in organizational innovation: the case of shared care in hearing aid provision. , 2007, Health services research.

[5]  J. Rubins,et al.  Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). , 2007, Chest.

[6]  M. Woronoff-Lemsi,et al.  Protocole IFCT-0302 : essai randomisé de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués , 2007 .

[7]  F. Shepherd,et al.  Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer? , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  J. Koeller,et al.  Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. , 2006, The oncologist.

[9]  R. Abrams,et al.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[11]  Ping Yang,et al.  Long-term survivorship in lung cancer: a review. , 2006, Chest.

[12]  J. Matthews,et al.  Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. , 2005, Lung cancer.

[13]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Dancey,et al.  Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. , 2004, Lung cancer.

[15]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[16]  Danny Rischin,et al.  Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[18]  T. Nakajima,et al.  Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[19]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[20]  S. Tyldesley,et al.  Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. , 2001, International journal of radiation oncology, biology, physics.

[21]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  John E. Connolly,et al.  Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. , 2000, AJR. American journal of roentgenology.

[23]  P. Wingo,et al.  Long-term cancer patient survival in the United States. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  M. Edelman,et al.  The Utility of Follow-up Testing After Curative Cancer Therapy: A Critical Review and Economic Analysis , 1997, Journal of General Internal Medicine.

[25]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[27]  M. Buxton,et al.  Economic Evaluation and Decision Making in the UK , 2012, PharmacoEconomics.

[28]  Milton C. Weinstein,et al.  Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.

[29]  A. Messori,et al.  Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer , 2012, PharmacoEconomics.

[30]  A. Messori,et al.  Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. , 2001, PharmacoEconomics.